Premium
P1‐127: In vivo drug discovery using a nontransgenic model of Alzheimer's disease with face, construct and predictive validity
Author(s) -
Villard Vanessa,
Givalois Laurent,
Maurice Tangui,
Roman François J.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.676
Subject(s) - donepezil , cholinergic , neuroprotection , acetylcholinesterase inhibitor , pharmacology , rivastigmine , galantamine , cholinergic neuron , in vivo , acetylcholinesterase , cognitive decline , neuroscience , psychology , medicine , chemistry , dementia , disease , biology , biochemistry , enzyme , microbiology and biotechnology
expression. Furthermore, treatment with the phosphatase inhibitor okadaic acid or the tubulin-binding toxin colchicine leads to hyperphosphorylation of tau and neurite degeneration. Conclusions: We conclude that the LUHMES system is well applicable for various pharmacological and biological assays and that it can be used to study the pathomechanisms underlying AD directly on a human neuronal background.